Table 2 Outcomes of clinical trials of single-agent bispecific antibodies or combination therapy

Target

BCMA/CD3

BCMA/CD3

BCMA/CD3

BCMA/CD3

GPRC5D/CD3***

BCMA/CD3 + GPRC5D/CD3

GPRC5D/CD3 + 

CD38

Drug

Teclistamab

Elranatamab

Linvoseltamab

F182112

Talquetamab

Teclistamab

 + Talquetamab

Talquetamab + Daratumumab

Patient Number

24

123

179

(200 mg: n = 75

50 mg: n = 104)

16

143(QW)

145(Q2W)

51(prior T therapy)

63

65

Median age (year)

66

(51–80)

68

(36–89)

66**

(37–90)

64

(52–74)

N/A

67

(39–81)

63

(37–81)

Median prior LOT

7

(4–13)

5

(2–22)

5**

(1–16)

≥ 4

(56%)

5–6

5

(1–11)

5

(2–16)

TCR MM

100%

96.7%

81%**

N/A

74%

69%

84%

78%

58%

Median time to response(mo)

0.53

NR

(95%CI, 12.9-NE)

N/A

N/A

N/A

N/A

1

(0.9–8.3)

ORR

60%

61%*

(95%CI, 51.8–69.6)

64%(include 12 patients in Phase I)

50%

43.8%

(95%CI, 19.8–70.1)

74%

73%

63%

84%

78%

≥CR

N/A

31.7%

N/A

N/A

(≥ VGPR)59%

               57%

               53%

34%

45%

Median follow-up(mo)

1.3

12.8

(0.2–22.7)

2.3

4.7

3.1

(0.9–11.7)

14.9

8.6

11.8

14.4

(0.5–21.9)

11.5

(1.0-27.3)

Median PFS(mo)

N/A

NR

N/A

N/A

7.5

11.9

5.1

N/A

19.4

Mediann OS(mo)

N/A

NR

N/A

N/A

N/A

N/A

N/A

12-mo PFS

N/A

57.1%

(95%CI, 47.2%-65.9%)

N/A

N/A

N/A

N/A

76%

12-mo OS

N/A

62%

(95%CI, 52.8%-70%)

N/A

N/A

N/A

N/A

93%

CRS/ICANs

Gr 1–2 CRS 41%

N/A

Gr1-2 CRS:36%

                  51%

Gr ≥ 3 ICANS:2%

                   1%

Gr 1–2 CRS: 81%

Gr1-2

CRS:79% ICANS:11%

        75%              11%

        77%               3%

Gr 1–2 CRS 78%;

Gr 3 CRS 3%;

ICANS :1patient

Gr 1–2 CRS 78%;

Gr 1–2 ICANS 5%

Infection

N/A

N/A

Gr1-2:17%;Gr ≥ 3:26%

          28%            31%

N/A

58%

65%

71%

N/A

63%

References

[4]

[5]

[6]

[7]

[8]

[9]

[10]